Lexeo Therapeutics, Inc. (LXEO)
Market Cap | 518.37M |
Revenue (ttm) | n/a |
Net Income (ttm) | -114.17M |
Shares Out | 54.00M |
EPS (ttm) | -3.20 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,007,896 |
Open | 9.23 |
Previous Close | 9.22 |
Day's Range | 9.23 - 10.04 |
52-Week Range | 1.45 - 11.72 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 18.13 (+88.85%) |
Earnings Date | Nov 12, 2025 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $18.13, which is an increase of 88.85% from the latest price.
News

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular dis...

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback
Lexeo Therapeutics received positive FDA feedback, enabling a faster path to Accelerated Approval for LX2006 in FA cardiomyopathy. Pooled phase 1/2 interim data for LX2006 show LVMI improvements well ...

Lexeo Therapeutics, Inc. - Special Call
Lexeo Therapeutics, Inc. - Special Call Company Participants Louis Tamayo - CFO & Principal Accounting Officer R. Townsend - CEO & Director Sandi Tai - Chief Development Officer Eric Adler - Chief Med...

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Inter...

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxi...

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for...

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Ge...

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned r...

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement
Lexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO regi...

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, anno...

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials
Lexeo Therapeutics, Inc. LXEO on Monday released interim data across all dose cohorts of LX2006 for Friedreich ataxia (FA) cardiomyopathy, a serious heart condition in FA patients with a rare, inherit...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, fratax...

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression...

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...

Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrate...

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in...

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.